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THE EFFECT OF LEFT- VERSUS RIGHT-SIDED CONTRAST INFUSION ON
ATTENUATION IN CHEST CT ANGIOGRAMS
Lars J. Grimm, Daniel Cornfeld, Hamid R. Mojibian. Department of Diagnostic
Radiology, Yale University, School of Medicine, New Haven, CT.
This study assesses if the arm of contrast infusion influences attenuation of the main
pulmonary artery in CT angiograms to evaluate for pulmonary emboli.
With IRB approval, 407 consecutive CT angiograms performed to exclude pulmonary
emboli were reviewed. Patient characteristics, study details, and interpretation results
were collected. After exclusion criteria were applied, 100 studies from each of our three
scanners (4, 16, and 64 slice) remained. A reader, blinded to injection side, reviewed the
images and recorded the attenuation of the main pulmonary artery.
The average post-contrast attenuation in the main pulmonary artery was similar if
infused through the right (275.4 HU) or left (275.0 HU) arm when controlling for
confounders with a multiple regression analysis (p = 0.82). There was no statistical
difference (p > 0.05) in the number of scans with attenuation less than 250 (45.9% right,
42.9% left), 200 (25.0% right, 29.0% left), or 150 HU (11.6% right, 12.3% left) and no
difference in the number of scans interpreted as indeterminate (1% right, 4% left) or nondiagnostic (3% right, 3% left).
Main pulmonary artery attenuation is not dependent on the arm of infusion when
evaluating mean attenuation, attenuation beneath thresholds of 250, 200, or 150 HU, or
indeterminate or non-diagnostic interpretations for patients undergoing a CT angiogram
of the chest to rule out pulmonary emboli.
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INTRODUCTION
Pulmonary emboli (PE) are a major cause of morbidity and mortality. Autopsy
studies list pulmonary emboli as a contributing underlying cause of death in as many as
33.9-37.3% of cases1, 2. The incidence of pulmonary emboli has not changed in the last
three decades, despite increased preventative measures and more routine anti-coagulation
therapy. Unfortunately, pulmonary emboli are very difficult to diagnose clinically and
are frequently only detected during autopsy. Although Well described a list of criteria for
the diagnosis of deep vein thrombi (DVT) in 1995, which is the most common source
location for pulmonary emboli, clinicians have continued to struggle with providing
accurate diagnoses3. The difficulty in diagnosis frequently results from non-specific
patient presentations and poor initial diagnostic tests. The classic clinical triad of
dyspnea, tachycardia, and chest pain are collectively found in only a minority of patients,
and are commonly the result of more benign processes. DVT are detected in less than
half of confirmed cases of pulmonary emboli, and both electrocardiogram and chest x-ray
abnormalities are equally poor indicators4. Although extremely sensitive, d-dimer assays
are only approximately 50% specific. False positive results can be secondary to age,
pregnancy, trauma, inflammatory disease, surgery, and liver disease. Unfortunately,
these confounders exist in the patient population that is at greatest risk for developing a
thromboembolism. As a result, without a test that is both sensitive and specific for
pulmonary emboli, it is extremely difficult for clinicians to adequately determine if a
patient has a pulmonary embolism.
Physicians must maintain a high index of suspicion for pulmonary embolism in any
patient who suffers from a sudden onset unexplained major event, such as chest pain,
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syncope, or arrhythmia, whether or not it appears cardiovascular in nature. The need for
prompt diagnosis is magnified by the large discrepancy that exists between the treated
and untreated mortality rates for patients who develop a pulmonary embolism. The
untreated mortality rate is 5% among ambulatory patients, and up to 30% for hospitalized
patients 5, 6. With prompt anticoagulation treatment the hospitalized mortality rate can be
reduced to less than 8%. Treatment for pulmonary emboli is most commonly via
anticoagulation therapy, usually with immediate short term heparin administration and
then long term with warfarin. Patients subsequently require frequent monitoring of blood
international normalized ratio (INR). Alternative treatment modalities for patients who
are poor candidates for anticoagulation are inferior vena cava filter placement, clot
thrombolysis, or surgical pulmonary thrombectomy. The initiation of anticoagulation
requires a careful analysis of the risk-benefit ratio tailored to the individual patient.
Patients undergoing anticoagulation therapy have a greatly increased risk of developing
hemorrhagic complications, and thus must be carefully monitored. Fortunately though,
the mortality rate for pulmonary emboli has declined dramatically over the last 20 years
thanks to better diagnostic and treatment methodologies. Age adjusted mortality rates
have reduced from 191 per million in 1979 to 94 per million in 19982. As a result, it is
especially important to ensure that the methods used to detect pulmonary emboli are both
quick and accurate, because the potential complications of a false positive or false
negative result may be fatal.
Although history, physical examination, and laboratory studies are the primary and
most important steps towards diagnosing a pulmonary emoblism7, there has been an
increased reliance on imaging to provide more definitive diagnoses. Ventilation-
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perfusion (V/Q) scans, pulmonary angiograms, and CT pulmonary angiography have
become the most well known radiologic methods for diagnosis. V/Q scans are the
traditional gold-standard methodology and as such, have been the most thoroughly
investigated means of detecting pulmonary emboli. Unfortunately, V/Q scans require
significant patient cooperation and are not readily available after normal hospital hours.
The outcome of a V/Q scan is dependent on the pretest probability of the patient having a
pulmonary embolism which is influenced by the primary care provider’s experience and
thus provides a less objective means of diagnosis. Although V/Q scans are still used for
patients who are especially sensitive to radiation, such as pregnant patients and young
woman of childbearing age, and those for whom the administration of contrast is not
possible, such as those with contrast allergies or renal failure, in most centers V/Q scans
have become the second line modality. Nonetheless, the long established role of V/Q
scans provides the basis upon which all subsequent studies and analysis are compared8.
Another modality for the detection of pulmonary emboli is pulmonary angiography
which relies upon an interventionalist threading a catheter into the pulmonary artery and
then injecting contrast material into the pulmonary artery underneath direct visualization.
Although this provides a real time and directly modifiable method of detecting emboli, as
well as the means to provide immediate treatment with target thrombolytics, it is
associated with significant risks. The procedure is minimally invasive but still carries a
risk of hematoma formation, arterial puncture, air embolism, catheter fracture and
migration, and insertion site infection. Additionally, it involves a variable volume of
contrast to be administered, and requires a significant level of personnel to be on call to
provide appropriate patient care during and after the procedure. The risk benefit ratio of
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the procedure is highly operator dependent, and therefore as the volume of conventional
angiograms decreases the concomitant risk thus increases. In comparison to CT
pulmonary angiograms, conventional angiograms today represent an increasingly small
fraction of the diagnostic studies used to diagnose pulmonary emboli. As a result,
pulmonary angiography has also become a second line modality for the detection of
pulmonary emboli.
In most hospital centers, CT angiography has emerged as the first line modality for the
detection of pulmonary emboli. The Prospective Investigation of Pulmonary Embolism
Diagnosis (PIOPED) II Study, whose results were initially published in The New
England Journal of Medicine9 and jointly in The American Journal of Medicine10 and
Radiology8, was a prospective, multicenter investigation assessing the utility of CT
angiography for the detection of pulmonary emboli. It is the largest and most current
database for the analysis of diagnosing pulmonary emboli with CT angiography.
Although the data is still being analyzed in further detail by additional investigators, the
PIOPED II Investigators conclude that CT angiography, when combined with a sound
clinical assessment, provides an excellent means of diagnosing pulmonary emboli with a
sensitivity of 83% and a specificity of 95%. Furthermore, they provide a stepwise
diagnostic tree which incorporates CT angiography into the workup of suspected
pulmonary emboli that is becoming the standard of care in major hospitals. Numerous
additional studies have established that when compared to V/Q scanning and catheter
angiography, CT angiography provides rapid, cost-effective, non-invasive, and reliable
diagnoses11-14. Traditionally, the greatest limitation of CT angiography has been poor
visualization of the peripheral pulmonary arteries, but the increased development and
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availability of multidetector-row spiral CT equipment has helped compensate for this
deficit11. The collective volume of literature supporting the use of CT angiography has
pushed it to become the current modality of choice for the diagnosis of pulmonary
embolism.
Although CT angiography is a powerful tool, there are still associated risks and
drawbacks. The visualization of a clot burden requires careful discrimination between
contrast enhanced blood and thromboembolism. This is achieved via a precisely timed
bolus of contrast material that is administered through a peripheral intravenous line.
Unfortunately, the administration of contrast carries an associated risk of contrastinduced nephropathy15, 16. Contrast-induced nephropathy is defined as a 25% increase in
the serum creatinine level compared to baseline. Patients whose creatinine exceeds a
threshold level, usually between 1.5 and 1.8 mg/dL, are not usually eligible for a contrast
based study, since compromised renal function is the major risk factor for contrastinduced nephropathy. The general risk of developing nephropathy after a radiologic
procedure is less than 3%; however, in specific patient populations the risk may increase
to as much as 20%17. Patients with diabetes and those with pre-existing renal disease are
at greatest risk for developing nephropathy. The associated neuropathy and sedentary
lifestyle that frequently accompanies these conditions also places these patients at
increased risk for pulmonary embolism. Patients who develop contrast-induced
nephropathy are more likely to die in-hospital and their 1-year mortality rates are
increased beyond their underlying medical conditions15. Although generally considered
routine, the administration of contrast material must be viewed as a calculated risk. The
benefit of detecting a pulmonary embolism in a moderate to high risk patient will usually

10

outweigh the potential for contrast nephropathy in most patients. However, even in
patients with pristine renal function, contrast material will affect their renal function such
that repeat scans require a washout period, usually at least 24 hours in most hospitals, to
allow kidney funtion to return to baseline. As a result, it is important to maximize the
information yield from a single CT angiogram for suspected pulmonary embolism,
because serial scanning is associated with a serial increase in risk.
The other major concern with CT angiography is the radiation exposure. Although
long known, there has been increased dialogue in both the academic literature and lay
press18, 19 recently regarding the quantity of radiation exposure, particularly from CT
scanning, and the potentially associated increased risk of developing cancer. It is
estimated that based on our current utilization of CT scans, 1.5-2% of all cancers in the
United States might be the result of CT-induced radiation exposure, up from 0.4% in the
period from 1991 to 199620. Furthermore, in large hospitals CT scanning accounts for
approximately 75% of the diagnostic radiation delivered to patients21. Young patients
and those who require repeat imaging are at greatest risk for developing radiation induced
complications in the future, because radiation-induced genetic changes accumulate over
the lifetime of an individual. As for contrast administration, the risk of radiation
exposure must be compared to the risk of missing the diagnosis of pulmonary embolism.
In the majority of situations, a single CT angiogram to detect a pulmonary embolism is
worth the associated radiation exposure, but it is imperative to reduce the need for repeat
imaging. Poor quality studies that provide indeterminate or non-diagnostic information
do not provide a yes/no diagnosis and exposure the patient to needless radiation and
contrast exposure. If patients have an inconclusive study, they are primarily at risk for
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complications associated with an undiagnosed and untreated pulmonary embolism, but in
many situations they will be subjected to repeat imaging at a later time which multiplies
the previously described risks associated with CT scanning. To maximize the utility of a
CT angiogram, it must be able to accurately detect a pulmonary embolism the first time.
As a result, there is a great deal of emphasis on tweaking the operational parameters in
order to optimize the information yield from a given study.
Identifying potential operational parameters for improvement is the first important
step. Jones and Wittram reported in Radiology, in 2005, that the two major causes of a
clinically indeterminate CT pulmonary angiogram study are motion artifact and poor
enhancement of the pulmonary vasculature22. In their study of 3612 CT pulmonary
angiogram examinations there were 237 indeterminate studies (6.6%). Only 81 of these
patients had follow up examinations of any sort within 5 days, defined as a repeat CT
pulmonary angiogram, conventional pulmonary angiography, V/Q scan, or lower
extremity ultrasound. 8% of those with indeterminate final interpretations were treated
empirically without definitive imaging. They discovered that the mean attenuation of the
main pulmonary artery was 339 HU +/- 88 in their control group, but only 245 HU +/- 80
in the group with indeterminate interpretations (p < 0.001). While motion artifact is
usually the result of old, slower scanners or patients who are either non-compliant or in
extremis, there are institutional protocols that can aid in patient compliance, including
pain medication or low level sedation in certain circumstances. However, enhancement
of the pulmonary vasculature can be maximized by optimizing certain operational
parameters. The study authors theorized that the reduced attenuation in the main
pulmonary arteries could be the result of technician error, anatomic variations, or
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decreased perfusion secondary to low cardiac output. Of these factors, technician error is
generally regarded to occur as a fixed percentage of cases, directly dependent on the
experience of the operator. Reduced perfusion secondary to a low cardiac output state
can be detected with a preliminary timing run, which is the standard protocol of choice on
many scanners. However, anatomic factors are a poorly discussed, but potentially very
influential means of altered attenuation values. If patients with certain anatomic
conditions which predispose them to poor attenuation examinations could be identified,
then compensatory mechanisms might be developed to overcome this obstacle.
Regardless of the etiology, every time a patient undergoes a CT angiogram that results in
an indeterminate reading, the patient is exposed to needless contrast and radiation,
without a concomitant increase in knowledge about their clinical status. Minimizing poor
quality CT pulmonary angiogram studies is clinically important, because repeat or follow
up scanning is not cost effective, delays a definitive diagnosis, and results in repeated
exposure to the very real side effects of contrast enhanced CT examinations.
The precise timing and delivery of a contrast bolus is the most important modifiable
factor affecting the information yield in a CT angiogram to evaluate for suspected
pulmonary embolism. There is a great deal of literature attempting to determine which
patient and study characteristics can maximize the information yield from a CT
angiogram, including age, gender, patient weight, and catheter size or position23, 24. At
our institution there has been increased discussion about the potential heterogeneity in
contrast delivery based on the arm of infusion. Anatomically, there is a difference in the
pathway of the left and right brachiocephalic veins as they cross from the shoulders to
join the superior vena cava in the central chest. The right brachiocephalic vein has a
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straight pathway from the shoulder to the superior vena cava, but as the left
brachiocephalic vein crosses the thorax to join the superior vena cava, it must cross in
front of the thick, muscular aortic arch. At this position, it is possible for the stiffer aortic
arch to compress the thinner-walled left brachiocephalic vein. There is a fixed amount of
space in the anterior-posterior diameter of the chest into which the aortic arch and the left
brachiocephalic vein must fit. The two situations in which compression of the left
brachiocephalic vein by the aortic arch might occur are via an increase in the area
occupied by the aorta or a by a decrease in the potential anterior-posterior space
available. Previous research has demonstrated that in patients with an elongated or
ectatic aortic arch, such as elderly patients with hypertension, compression of the left
brachiocephalic vein may occur25, 26. A compressed left brachiocephalic vein would limit
the flow of blood from the left arm to the pulmonary arteries, and in the process reduce
the rate of contrast delivery. This could dilute the volume of contrast received, reduce
attenuation, and result in a poorly visualized examination of the pulmonary arteries,
specifically in the periphery which is the region of greatest limitation for CT
angiography.
Under ideal circumstances, contrast is administered in a rapid bolus that floods the
anatomic region of interest in order to maximize attenuation of the vessel in question,
with minimal attenuation of the surrounding vessels in order to reduce background noise.
Figure 1a shows a theoretical attenuation over time curve under ideal circumstances. The
rapid contrast bolus, if unrestricted in its passage, results in a steep attenuation curve.
This value must cross a specific threshold to ensure that the vessels in question are
adequately attenuated to be visualized by the radiologist. In this graph, the integral of the
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curve is related to the total volume and rate of contrast administered, but in order to limit
potential renal complications, the volume of contrast should be kept as low as possible.
Increasing the rate of contrast delivery will increase the slope of the attenuation curve,
but is technically limited by the route of administration (i.e. the bore of the intravenous
line and the speed with which the contrast can be pushed) and the total volume to be
given (i.e. injecting fast equates to injecting more). In order to maximize vessel
attenuation while limiting potential renal complications, the minimal amount of contrast
must be administered in as rapid a fashion as possible in order to keep the integral of the
attenuation curve low and maximize the peak attenuation. If there is a delay in the
delivery, for whatever etiology, then the value of the integral remains unchanged, but the
slope decreases, causing the peak of the curve to be depressed and shift to the right. With
a small delay in attenuated blood flow, there may be a subclinical reduction in peak
attenuation, as shown in Figure 1b, because the peak attenuation value still crosses the
attenuation threshold for the duration of the scan. As the delay increases, the slope of the
attenuation curve flattens, leading eventually to a subclinical peak attenuation value in
which the entirety of the scan is not above threshold, as shown in Figure 1c. Contrast
administered from a peripheral intravenous line is continually mixed with non-attenuated
blood as additional vessels join or as the central vessel merges with others. This results
in a stepwise dilution first in the superior vena cava where the two brachiocephalic veins
merge, and again in the right heart as blood from the inferior vena cava is introduced.
This normal dilution is compensated by administering a volume of contrast large enough
to ensure there is adequate attenuation in the distal region of interest. In the case of left
brachiocephalic vein occlusion, compression by the aorta could reduce the flow of
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attenuated blood into the superior vena cava. This reduction in blood flow is vessel
specific, and not a systemic slowing, thus the proportional volume of attenuated blood
entering the pulmonary vessels from the left brachiocephalic vein would be decreased.
Since attenuation is dependent on the concentration within a vessel, this would lead to a
decrease in the attenuation of the pulmonary vasculature, while still exposing the patient
to the full volume, and the associated risks, of contrast administration. In certain
circumstances, this reduction in flow may be severe enough to result in an attenuation
peak that does not cross the attenuation threshold, or more likely, the attenuation is not
above the threshold for the entire duration of the scan resulting in inconsistent image
capture.
Although a theoretical risk for chest CT angiograms, there is a growing body of
literature describing the influence of brachiocephalic vein occlusion in CT and MR
imaging of the head and neck. Brachiocephalic vein compression influencing crosssectional imaging was first reported in 1977 in the head and neck literature in the Journal
of Nuclear Medicine as an incidental finding during brain flow imaging27. Although head
and neck CT angiograms are subject to the same mechanistic, timing, and contrast
delivery restrictions as chest imaging, the means of detecting occlusion are more readily
apparent. Compression of the left brachiocephalic vein pools attenuated blood proximal
to the merging of the vein with the superior vena cava28, 29. In approximately 6% to 13%
of the population, there exists either a congenital or acquired, usually the result of
longstanding hypertension, absence of jugular venous valves30. Venous valves are
designed to ensure unidirectional flow of blood, but when they are absent and there is
downstream obstruction, then retrograde flow of contrast material from the
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brachiocephalic vein up the left jugular vein and into the dural sinuses may occur. Upon
image capture, the early arterial phase sequences are complicated by artifact from the
refluxed venous contrast, leading to poor quality studies. In up to 9.1% of studies,
increased artifacts and poor visualization were directly the result of left-sided
brachiocephalic vein occlusion and retrograde flow31-33. This phenomenon has been
extensively identified and described during both CT and MR imaging26, 30, 34, 35, and
several published series propose that for head and neck imaging, right-sided contrast
infusion should be the new standard of care. As a direct result of the anatomic region of
coverage imaged, head and neck imaging is especially sensitive at detecting
brachiocephalic vein occlusion.
To our knowledge, there are no published series that have looked at the impact of leftversus right-sided injections on attenuation of the pulmonary arteries in patients
undergoing CT angiograms of the chest to evaluate for pulmonary emboli. Theoretically,
the same process which limits left-sided contrast administration in CT angiograms of the
head and neck may be apparent in CT angiograms of the chest, although the means of
detection may by nature be more subtle because of the anatomic region imaged. In the
authors’ experience, they have anecdotally witnessed occlusion of the left
brachiocephalic vein by the aorta, and subsequent retrograde flow of contrast material up
the left jugular vein. This has resulted in a poor quality bolus delivered to the pulmonary
vasculature, requiring repeat imaging to allow for adequate visualization of the distal
pulmonary arteries in order to rule out pulmonary emboli. Because of the time sensitive
nature of identifying pulmonary emboli, as well as the associated risks of radiation and
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contrast exposure, it is very important to identify any factors, such as arm of infusion,
which may result in poor quality studies.

STATEMENT OF PURPOSE
This study is an outcomes based analysis that seeks to determine if the side of contrast
infusion influences the attenuation of the main pulmonary artery in patients undergoing a
CT angiogram of the chest to evaluate for pulmonary emboli. Although a mechanism for
a difference has been discussed based on previous published research, our analysis seeks
to determine if a difference exists rather than to identify any potential etiologies. The
primary outcomes are post-contrast attenuation in Hounsfield Units (HU) of the main
pulmonary artery. The secondary outcomes are the number of studies beneath an
attenuation threshold of 250, 200, and 150 HU, and the number of studies interpreted as
non-diagnostic or indeterminate. Tertiary analysis will seek to determine if there is an
age dependent shelf affect that results in an attenuation difference. We hypothesize that
there exists a difference in the attenuation of the main pulmonary artery based on the
arm of infusion in patients undergoing a CT angiogram of the chest to evaluate for
pulmonary emboli.

MATERIALS AND METHODS
This retrospective study was performed solely at the Yale-New Haven Hospital.
Approval for the study was obtained through the institutional Human Investigation
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Committee (HIC). The study was compliant with the guidelines of the Health Insurance
Portability and Accountability Act (HIPAA) and a waiver of informed consent was
obtained. All work was undertaken by the primary author except when noted otherwise,
as in the image review section.

Study Selection
A list of studies was generated from our institutional computer database (IDX, GE
Medical Systems) by searching for the billing code for CT pulmonary angiograms
performed on each of our three CT scanners beginning June 1, 2006. This date was
chosen to predate the increase in institutional dialogue regarding the potential
heterogeneity in arm of infusion attenuation. To our knowledge, there have been no
systemic efforts to insert intravenous lines in a specific arm as a result of this dialogue,
but we cannot rule out non-institutionalized preferences. Consecutive studies were
evaluated from each scanner. A sample size of 300 was chosen based on preliminary
power calculations that showed this would allow us to detect attenuation differences of
25 HU with a p = 0.05 at a power of 80%.

Exclusion Criteria
Studies were excluded for a variety of technical, procedural, or structural reasons. If
the full bolus of contrast was not administered due to technical or mechanical failure,
then the study was excluded because the exact volume and rate of infusion could not be
determined. This most commonly occurred as a result of extravasation of contrast at the
intravenous line site and frequently resulted in a repeat examination, both of which were
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ineligible for inclusion. Residual contrast material that had not been adequately cleared
by the initial bolus could create artificially elevated attenuation readings. Less
commonly, mechanical malfunction resulted in only a partial bolus of contrast
administration. Although a strict protocol guideline associated with the volume of
contrast to be administered was in place, if the quantity of contrast injected was not
recorded by the CT technician, we did not assume homogenous contrast volume
administration and the study was excluded. Finally, if a patient had a repeat CT scan to
evaluate for pulmonary embolism and both studies were within the eligibility time frame,
only the first study was considered eligible for inclusion in the final analysis, so as to
prevent duplicate assessment of an individual’s anatomy.
Dialysis patients were excluded because of the high probability for iatrogenic changes
in their peripheral vasculature secondary to shunt placement or repeated vascular
manipulation, which may lead to altered flow patterns. The field of view of the CT scan
does not include the full length of the arm vasculature so it was impossible to determine
which patients had altered vasculature. Also, repeated prior catheter insertion could
result in local stenosis. Patients with a central venous thrombus have reduced flow of
contrast material to the pulmonary vessels that was unrelated to the structural phenomena
we were trying to assess and were excluded if identified by the primary radiologist’s
interpretation. Although all patients are supposed to have contrast administered via a
peripheral intravenous line, in rare situations a central line was used and these studies
were excluded. Central lines bypass the subclavian and brachiocephalic vessels and
administer contrast directly to the superior vena cava or the right atrium, thus removing
any potential brachiocephalic occlusion from consideration. Finally, patients with a
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repair from congenital heart disease may have completely distorted structural anatomy
and flow patterns and could not be standardized in our analysis.

Hardware and Technique
Scans were performed on our three institutional CT scanners. Scanner 1 was a 4-slice
GE LightSpeed (GE Medical Systems). A smartprep, in which low-dose scanning is
performed in a designated region of interest (ROI) until an attenuation threshold is
breached, was performed at the level of the main pulmonary artery. Scanning of the
chest began 3 seconds after the technologist detected a pulmonary artery enhancement of
100 HU in the designated ROI. A total of 100 cc of contrast was administered at a rate of
4 cc/sec followed by 10 cc saline at 4 cc/sec. 2.5 mm thick images were acquired using
120 kVP and SmartMA dose modulation with the noise index set to 15.
Scanner 2 was a 16-slice GE LightSpeed. A timing run was performed at the level of
the main pulmonary artery using 25 cc of contrast injected at 4 cc/sec followed by 10 cc
saline at 4 cc/sec. Timing was determined by peak pulmonary artery enhancement as
measured by ROI analysis. CT angiogram images were obtained following a second
injection of an additional 90 cc of contrast at 4 cc/sec followed by a 10 cc saline at 4
cc/sec. 1.25 mm thick images were acquired using 120 kVP and SmartMA dose
modulation with the noise index set to 11.
Scanner 3 was a 64-slice GE VCT. A timing run was performed at the level of the
main pulmonary artery using 25 cc of contrast injected at 4 cc/second followed by 10 cc
saline at 4 cc/sec. Timing was determined by peak pulmonary artery enhancement as
measured by ROI analysis. CT angiogram images were obtained following a second
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injection of an additional 90 cc of contrast at 4 cc/sec followed by a 10 cc saline at 4
cc/sec. 1.25 mm thick images were acquired using 120 kVP and SmartMA dose
modulation with the noise index set to 20.
All scans used Omnipaque 350 (Amersham, Piscataway NJ) contrast material injected
through an 18 gauge or larger upper extremity peripheral intravenous line.

Chart Review
One researcher was designated to perform the initial chart review to screen for eligible
studies from among the computer generated list of CT pulmonary angiograms. Studies
were reviewed chronologically. Potential exclusion criteria were identified in either the
formal radiology report or the study order form completed by the requesting clinician.
Studies that met eligibility criteria were assigned a unique study identifier for subsequent
use. The following variables were recorded from the radiology report and order form:
age, gender, history or diagnosis of congestive heart failure (CHF), scanner used, contrast
quantity, pacemaker presence, and radiologist study interpretation, recorded as positive,
negative, indeterminate, or non-diagnostic. In our experience, indeterminate and nondiagnostic interpretations are reader specific means of indicating that the study was not
performed adequately to justify a formal reading. No reinterpretations of the images
were made.

Image Review
The selected study image series were transferred from the hospital PACS system
(Synapse, FujiFilm; Stamford CT) to a Vitrea graphics workstation (Vital Images;
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Minnetonka MN) by the initial chart reviewer. This researcher then recorded the side of
injection by identifying the attenuated brachiocephalic and subclavian vessels at the
imaging workstation. A consecutive stack of images through the main pulmonary artery
and its bifurcation were then selected and saved to the workstation, as shown in Figure 2.
The remaining images in the series were deleted from the workstation. The saved images
did not include the superior aspect of the series, thus removing the brachiocephalic
vessels. From the saved images, it was not possible to determine from which side the
contrast was injected upon subsequent review. A new de-identified list of these prepared
images was created, which did not contain any of the previously collected information
from the chart review.
A separate researcher with 7 years of experience reading CT pulmonary angiogram
examinations received the list of prepared images. The researcher was thus blinded to the
side of infusion and to all clinical information regarding the saved images. An ROI was
placed within the center of the main pulmonary artery, as determined by drawing lines
along the long and short axis of the vessel and placing the ROI at the intersection, as
shown in Figure 3. The diameter of the ROI was made equal to the radius of the artery.
The researcher ensured that there was no volume averaging by checking that the slice
immediately above and below also contained the main pulmonary artery. The average
attenuation value in Hounsfield Units of the ROI and the area of the ROI were recorded.

Statistical Analysis
After the chart review and the image analysis, the two lists were merged. The mean
attenuation of the main pulmonary artery for the right and left arm cohorts were
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calculated and 95% confidence intervals were determined. Statistical significance was
computed using a two tailed, non-paired t-test. Multiple regression analysis was
performed to control for potential confounders: gender, age, contrast volume, region of
interest area, CHF status, and pacemaker presence.
The number of scans beneath the 250, 200, and 150 HU thresholds and the number of
studies interpreted as non-diagnostic or indeterminate were compared using a Chisquared analysis. The threshold value of 250 HU was determined based on a review of
the literature regarding adequate attenuation for CT pulmonary angiograms to rule out
pulmonary emboli 22, 36. The addition of 200 and 150 HU threshold values were made
based on preferences of multiple readers at our institution. A p value of less than 0.05
was considered statistically significant. Data was collected and analyzed using the
software programs Excel (Microsoft; Seattle WA) and SPSS (SPSS; Chicago IL).

RESULTS
Figure 4 shows the distribution of studies included and excluded in the analysis. 407
total studies were reviewed to obtain a sample of 300 studies, with 100 from each
scanner. The most common etiology of exclusion was failure by the technician to record
the volume of contrast material delivered in the study, followed by infiltrated intravenous
lines, central line delivery, dialysis, and congenital heart disease repair. No central
venous thrombi were identified.
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The baseline study sample characteristics are shown in Table 1 for each scanner and in
aggregate. There was no statistically significant difference in the distribution of age,
gender, CHF status, pacemaker presence, ROI area, or contrast volume administered for
the left- and right-sided injection groups on any individual scanner or across the study
sample as a whole.

Table 1 – Study baseline characteristics. P values are > 0.05 based on Chi-squared
analysis. ROI = region of interest, CHF = congestive heart failure
All Scanners

Scanner 1

Scanner 2

Scanner 3

Total = 300

Total = 100

Total = 100

Total = 100

Right

Left

Right

Left

Right

Left

Right

Left

Studies
(%)

146 / 300
(48.7)

154 / 300
(51.3)

47 / 100
(47)

53 / 100
(53)

51 / 100
(51)

49 / 100
(49)

48 / 100
(48)

52 / 100
(52)

Age, years
(SD)

55.0
(19.8)

57.5
(17.3)

55.5
(22.1)

58.8
(18.0)

56.1
(17.7)

56.6
(16.9)

53.3
(20.0)

57.1
(17.4)

Female
(%)

93 / 146
(64)

84 / 154
(55)

27 / 47
(57)

32 / 53
(60)

33 / 51
(65)

26 / 49
(53)

33 / 48
(69)

26 / 52
(50)

CHF (%)

2 / 146 (1)

1 / 154
(1)

0 / 47 (0)

0 / 53 (0)

1 / 51
(2)

1 / 49
(2)

1 / 48
(2)

0 / 52
(0)

Pacemaker
(%)

2 / 146 (1)

0 / 154
(0)

0 / 47 (0)

0 / 53 (0)

2 / 51
(4)

0 / 49
(0)

0 / 48
(0)

0 / 52
(0)

ROI Area,
mm2 (SD)

193.5
(77.5)

201.8
(73.8)

155.0
(42.6)

166.3
(39.4)

206.4
(86.5)

212.4
(86.1)

217.5
(81.0)

228.1
(75.3)

Contrast,
mL (SD)

101.6
(7.8)

101.4
(7.2)

100.0 (0)

101.3
(7.3)

104.1
(12.5)

101.0
(7.1)

100.4
(2.9)

101.9
(7.2)
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The average attenuation of the main pulmonary artery and the 95% confidence
intervals are shown in Table 2 for each scanner and in aggregate. The distribution of the
attenuation values for the left- versus right-sided injection groups broken down into 25
HU increments are shown in Figure 5. There was no statistically significant difference in
the average attenuation between patients injected with contrast from the left or the right
arm. The average attenuation of the main pulmonary artery in patients injected in the
right arm was 275.4 HU (95% CI 255.6 to 295.1 HU). The average attenuation of the
main pulmonary artery in patients injected in the left arm was 275.0 HU (95% CI 257.3
to 292.8 HU). Multiple regression analysis showed no confounding factors among the
baseline characteristics collected and shown in Table 1.

Table 2 – Mean scanner attenuation values. P values are > 0.05 based on t-test analysis.
All Scanners

Attenuation,
HU (95% CI)

Scanner 1

Scanner 2

Scanner 3

Right

Left

Right

Left

Right

Left

Right

Left

275.4
(255.6 –
295.1)

275.0
(257.3 –
292.8)

244.7
(219.2 –
270.1)

229.7
(206.2 –
253.2)

229.1
(205.3 –
253.0)

242.0
(215.2 –
268.9)

354.5
(314.3 –
394.7)

352.3
(322.3 –
382.2)

Table 3 displays the values of the secondary endpoints under consideration: threshold
attenuations and study interpretation results. There was no statistically significant
difference in the number of scans below threshold attenuation values of 250 HU (67
(45.9%) right, 66 (42.9%) left), 200 HU (37 (25.3%) right, 45 (29.2%) left), and 150 HU
(17 (11.6%) right, 19 (12.3%) left). There was no statistically significant difference in
the number of scans interpreted as non-diagnostic (4 (2.7%) right, 4 (2.6%) left) or
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indeterminate (2 (1.4%) right, 6 (3.9%) left). Although not a primary or secondary
endpoint, there was incidentally also no statistically significant difference in the number
of positive (20 (13.7%) right, 31 (20.1%) left) or negative (120 (82.2%) right, 113
(73.4%) left) study interpretations.

Table 3 – Outcomes of analysis. P values are > 0.05 based on Chi-squared analysis.
All

Scanner 1

Scanner 2

Scanner 3

300 scans

100 scans

100 scans

100 scans

Right

Left

Right

Left

Right

Left

Right

Left

Attenuation <
250 HU (%)

67 / 146
(45.9)

66 / 154
(42.9)

28 / 47
(59.6)

30 / 53
(56.6)

32 / 51
(62.7)

30 / 49
(61.2)

8 / 48
(16.7)

5/52
(9.6)

Attenuation <
200 HU (%)

37 / 146
(25.3)

45 / 154
(29.2)

15 / 47
(31.9)

22 / 53
(41.5)

18 / 51
(35.3)

18 / 49
(36.7)

5 / 48
(10.4)

4 /52
(7.7)

Attenuation <
150 HU (%)

17 / 146
(11.6)

19 / 154
(12.3)

6 / 47
(12.8)

8 / 53
(15.1)

8 / 51
(15.7)

8 / 49
(16.3)

3 / 48
(6.3)

3 /52
(5.8)

Positive (%)

20 / 146
(13.7)

31 / 154
(20.1)

9 / 47
(19.1)

11 / 53
(20.8)

5 / 51
(9.8)

9 / 49
(18.4)

6 / 48
(12.5)

11 /2
(21.2)

Negative (%)

120 / 146
(82.2)

113 / 154
(73.4)

36 / 47
(76.6)

37 / 53
(69.8)

43 / 51
(84.3)

37 / 49
(75.5)

41 / 48
(85.4)

39/52
(75.0)

Non-Diagnostic
(%)

4 / 146
(2.7)

4 / 154
(2.6)

1 / 47
(2.1)

1 / 53
(1.9)

2 / 51
(3.9)

3 / 49
(6.1)

1 / 48
(2.1)

0 / 52
(0)

Indeterminate (%)

2 / 146
(1.4)

6 / 154
(3.9)

1 / 47
(2.1)

4 / 53
(7.5)

1 / 51
(2.0)

0 / 49
(0)

0 / 48
(0)

2 / 52
(3.8)

Table 4 displays the tertiary analysis for age bracketed outcomes. Primary and
secondary outcomes under consideration are broken down for patients greater than 60,
70, 80, and 90 years of age. There was no statistically significant difference in the arm of
infusion, mean attenuation, scans beneath threshold attenuation values of 250, 200, and
150 HU, or indeterminate and non-diagnostic readings for any of the age groupings. The
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total number of studies included in each age group progressively shrinks to only 6
subjects for the greater than 90 year age bracket.

Table 4 – Age bracketed outcomes. P values are >0.05 based on Chi-squared analysis.
Age, years
> 60

> 70

> 80

> 90

Total = 127

Total = 76

Total = 31

Total = 6

Right

Left

Right

Left

Right

Left

All Scanners
(%)

59 / 127
(46.5)

Attenuation,
HU (95% CI)

Right

Left

68 / 127
(53.5)

40 / 76
(52.6)

36 / 76
(47.4)

14 / 31
(45.2)

17 / 31
(54.8)

4/6
(66.7)

2/6
(33.3)

304.6
(265.9 –
343.4)

305.1
(274.0 –
336.2)

334.4
(282.3 –
386.5)

338.3
(295.0 –
381.6)

405.6
(310.4 –
500.7)

388.8
(336.6 –
441.1)

523.0
(229.3 –
816.7)

252.5
(157.4 –
347.6)

Attenuation <
250 HU (%)

23 / 59
(38.9)

24 / 68
(35.2)

14 /40
(35.0)

8 / 36
(22.2)

2 / 14
(14.2)

1 / 17
(5.9)

1/4
(25.0)

1/2
(50.0)

Attenuation <
200 HU (%)

14 / 59
(23.7)

19 /68
(27.9)

9 /40
(22.5)

7 / 36
(19.4)

2 / 14
(14.2)

0 / 17 (0)

1/4
(25.0)

0 / 2 (0)

Attenuation <
150 HU (%)

6 / 59
(10.2)

5 /68
(7.4)

3 / 40
(7.5)

1 / 36
(2.8)

1 /14
(7.1)

0 / 17 (0)

1/4
(25.0)

0 / 2 (0)

Non-Diagnostic
(%)

2 /59
(0.3)

2 / 68
(3.0)

0 / 40 (0)

0 / 36 (0)

0 / 14 (0)

0 / 17 (0)

0 / 4 (0)

0 / 2 (0)

Indeterminate
(%)

0 /59 (0)

2 / 68
(3.0)

0 / 40 (0)

0 / 36 (0)

0 / 14 (0)

0 / 17 (0)

0 / 4 (0)

0 / 2 (0)
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DISCUSSION
Our analysis demonstrates no statistically significant difference in the mean postcontrast attenuation of the main pulmonary artery between patients receiving a contrast
injection through the left or right arm. The baseline distribution of potential confounding
factors was similar between these two groups and the multiple regression analysis
demonstrated that age, gender, CHF status, pacemaker presence, contrast volume, and
ROI area were not independently confounding factors. We were also not able to discern
a statistically significant difference in the secondary endpoint attenuation thresholds or
study interpretations results. Tertiary analysis did not reveal an age dependent shelf
effect for attenuation variation.
There are no established minimum attenuation criteria for CT angiograms to rule out
pulmonary emboli currently available in the literature. In our experience, most
radiologists do not have a specific Hounsfield Unit requirement. They will attempt to
read the examination and instead report that it is a poorly attenuated study which may not
completely rule out emboli and if clinically suspicious might warrant a repeat
examination. Our decision to use a 250 HU threshold was based on the work of Wittram
et al. who recently presented in Radiology a series of chest CT angiograms positive for
pulmonary emboli37. They discerned that the average attenuation was 33 HU with a
standard deviation of 15 for acute pulmonary emboli and 87 HU with a standard
deviation of 31 for chronic pulmonary emboli. This increased attenuation of chronic
pulmonary emboli was attributed to clot organization, calcification, or local hemoglobin
iron concentration. To reach a value of 250 HU, they statistically extrapolated their
results to minimize false negatives. Three standard deviations above the mean would
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include 99.75% of all emboli, and then an additional standard deviation would be needed
to differentiate clot from surrounding blood36. For acute thrombi, with a maximum
attenuation of 78 HU, the blood must be attenuated to 91 HU, and for chronic thrombi,
with a maximum attenuation of 180, the blood must be attenuated to 211 HU. From this
value, 250 HU and 200 HU were deemed appropriate thresholds for our study, with 150
HU providing a more restricted outlier. Although Wittram et al.’s results provide a very
useful starting point, their sample size of 39 warrants additional investigation before
more concrete criteria can be established. In our study population we did not
differentiate between chronic and acute emboli; however, from the perspective of the
radiologist who is blinded to the duration of any potential clot the higher attenuation
value seems to be more clinically appropriate.
The differential attenuation threshold identified by Wittram et al. does raise the issue
of whether patients should be triaged to receive different infusion protocols. Since
nephrotoxicity is directly related to the volume of contrast administered, it is important to
utilize the least amount of contrast appropriate to receive adequate attenuation. Although
the majority of patients who are diagnosed with a pulmonary embolism do not present
with the classically described symptoms, for the subset of the population who are at low
risk for chronic embolism and who have a clearly timed symptomatic onset it might be
appropriate to utilize a protocol with a smaller volume of administration. Based on
Wittram et al.’s calculations, the maximum acceptable attenuation for identifying acute
thrombi is less than half that of chronic thrombi, 91 HU versus 211 HU. The lower risk
of nephrotoxicity must be balanced against the risk of repeating the examination
secondary to lower than acceptable attenuation.
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There are two possible scenarios in which compression of the left brachiocephalic
vein might influence CT angiogram results. Compression might occur on a systemic
basis, such that in every examination there is a reduction in flow with left-sided injections
to varying degrees. In this situation, we would expect to see a difference in the average
attenuation between left and right arm injections, with the magnitude of the difference
equal to the consistency in the degree of obstruction. However, the mean post-contrast
attenuations of the main pulmonary artery were nearly identical, with significant overlap
when confidence intervals are taken into consideration, as shown in Figure 6.
Additionally, we would expect to find a differential increase in the number of studies that
are below the threshold attenuation values. However, there is not only no difference in
the distribution of studies beneath the 250, 200, and 150 HU thresholds, there is also no
appreciable difference on a course visual analysis of the scan attenuation distribution, as
shown in Figure 5. These surrogates indicate that compression does not appear to be
occurring on a consistent basis.
The other scenario is if compression of the left brachiocephalic vein occurs
sporadically, such that only in certain circumstances is flow reduction present. In this
case we might not find a difference in the mean attenuation, but we would expect to see a
difference in the number of studies beneath the different attenuation thresholds for
individuals injected via the left or right arm. As noted above, this is not the case.
Furthermore, we would expect to find a difference in the number of indeterminate or nondiagnostic interpretations, which are the clinical expressions of low attenuation
examinations. However, this difference is not apparent indicating that even if there is a
difference on the anatomic level, this difference is not significant enough to translate
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clinically into non-decisive radiology reports. Therefore, it is unlikely that compression
is occurring sporadically to a degree which our mechanisms can identify.
Interestingly, despite the difference in the scanner protocols, there was no identifiable
difference between the attenuation values for the individual scanners. Scanner 1 relies on
a single contrast administration with ROI threshold triggering to initiate scanning,
whereas scanners 2 and 3 both utilize timing runs with two phase contrast administration.
Although this resulted in mean global attenuation differences between scanners, it
resulted in a statistically insignificant difference within scanners for left versus right arm
of infusion. Brachiocephalic vein occlusion should result in a delay in the upstroke of the
attenuation over time curve, leading to a wider and flatter curve as opposed to the ideal
brisk upstroke, as shown in Figure 1a-c. If the slope of the curve is shallow enough, then
the peak attenuation might never reach a clinically significant level, despite an equal area
under the curve. Presumably, timing runs should better accommodate upstream
occlusion because they look at the entire spectrum of the contrast bolus delivered, and
even if there is a delay they will still be able to pace the scanner to accommodate the peak
attenuation value. However, triggering protocols assume a continual rate of increase in
attenuation. They are set for a lower than peak attenuation value on the assumption that
the attenuation curve is on the rapid upslope and will continue to increase after the set
value is breached. In the case of a slower attenuation upstroke, then this could result in a
scan time that either precedes the peak attenuation or misses it, and may thus be beneath
the attenuation threshold necessary for an adequate clinical examination. However, the
lack of a statistically significant difference for both protocols presumes that there is
neither a decrease in the maximum peak of the attenuation over time curve, nor a
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decrease in the slope of the upstroke component under the conditions monitored in our
study.
The difference in identifiable outcomes between the pulmonary vasculature in our
study and that found in the head and neck literature, as described in the introduction,
could be the result of several factors. First of all, retrograde flow of small amounts of
contrast material into the jugular vein and dural sinuses causes venous artifact of the
arterial structures, thus making the head and neck very sensitive to regurgitation. Based
on our results, even if there is some reflux up the internal jugular vein, it is not significant
enough to affect the attenuation in the main pulmonary artery (i.e. it does not cripple the
utility of the contrast bolus). Additionally, the volume of contrast and tissue imaged is
grossly different between the two regions. Head and neck CT angiograms typically use
60 – 80 mL of contrast, rather than the 100 mL used in chest imaging, and by the time
this contrast reaches the head and neck it has been diluted to a greater extent than in the
pulmonary vasculature. Brachiocephalic vein occlusion should have a fixed impact on
contrast flow, thus producing a disproportionately larger influence on the head and neck
vessels. As such, it is possible that our mechanisms of detecting brachiocephalic vein
occlusion are not as sensitive as in the head and neck. We were unable to detect a
clinically significant difference though in terms of inconclusive study interpretations,
unlike the head and neck literature, which advocates that even if the effect is too small for
our tools of detection then it is not clinically important.
It is also possible that occlusion is occurring during head and neck imaging but not
during chest CT angiograms. This may be the result of procedural factors occurring
during imaging that are different between the two protocols utilized. Several authors
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have hypothesized that brachiocephalic vein compression may be reduced during deep
inspiration because of the increase in the anterior to posterior diameter of the chest, thus
reducing aorta-brachiocephalic compression26. During cross-sectional imaging of the
head and neck, patients are asked to respire at a tidal volume, whereas during imaging of
the chest, patients are asked to inspire deeply and hold their breath for the duration of the
scan. The difference in the depth of inspiration could be enough to reduce the
compression of the brachiocephalic vein to a subclinical level. Additionally, the
positioning of the patient’s arms during the two studies is different. In cranial imaging,
the patients are told to keep their arms at the side, but during chest imaging the arms are
raised overhead. Although one might hypothesize that upraised arms might induce a
thoracic outlet-like effect, this effect should be equally influential for both arms, and not
susceptible to the arm of infusion.
The results indicate several possibilities regarding the phenomena of brachiocephalic
vein occlusion. If brachiocephalic vein compression occurs in the setting of CT
pulmonary angiograms for PE evaluation, it appears to have a subclinical effect, either
because the brachiocephalic vein diameter is not sufficiently occluded to diminish flow or
the volume of contrast administered is enough to overcome any restriction in flow.
Future research focusing on the brachiocephalic vein as it crosses the arch of the aorta
would be necessary to further clarify this possibility. Either real time, direct visualization
of the vessel diameter during simulated conditions or a comparison of the vessel
attenuation immediately before and after it crosses the arch of the aorta might provide
useful insights, rather than the surrogate indicators used in this study and others.

34

Despite the negative outcomes found in this study, it is possible that there may be
subgroups of patients that our analysis was not extensive enough to cover but for whom a
difference in clinical outcome might still be apparent. Patients who are unable to produce
an appropriate inspiratory effort or who are unable to hold their breath might not increase
the anterior-posterior diameter of their chest enough to escape aorta-braciocephalic
compression. Patients with absent venous valves, narrow anterior to posterior chest wall
anatomy, and exceptionally ectatic aortic arches may still be at risk for insufficient
contrast delivery to the pulmonary vasculature if infusion is through the left arm.
Attempts to address this issue were made through repeat subgroup analysis. We used
patient age bracketing to see if there is a shelf effect that may not have been detected by
the multiple regression analysis because of the smaller sample size available for these
extremes of age. We might expect to identify an attenuation difference secondary to
changes that are acquired over the lifetime of an individual: aortic ectasia, incompetent
valves, reduced forward flow of blood, and restricted chest wall motion. Table 4 shows
the primary and secondary endpoints distributed over different decades of life. Although
there were no statistically significant differences identified, these calculations are limited
by the sample sizes, and some conclusions can still be reached. The average attenuation
for the over 80 and 90 age brackets begin to diverge between arms of infusion with rightsided infusions attenuating more than left-sided. Additionally, there is an increase in the
number of patients who are beneath the various attenuation thresholds for the over 70, 80,
and 90 age brackets; however, right-sided infusions make up a larger share. There was
no difference in the number of indeterminate or non-diagnostic interpretations.
Ultimately though, the average attenuation values in the main pulmonary artery in these
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more senior age groups are all well above even the most stringent threshold values for a
diagnostic study (250 HU).
From an outcomes standpoint, our data indicate that it does not matter which side a
patient receives the contrast bolus for a CT pulmonary angiogram to evaluate for PE.
Anecdotally, we are aware of some clinicians and institutions that mandate that patients
have a right-sided intravenous line, except in emergent cases. Our analysis demonstrates
that there is no need to delay the time to diagnosis and treatment for pulmonary embolism
by insisting that patients have venous access on a specific side.
There are several limitations to our study. There exists the potential for systemic bias
regarding why a particular arm was chosen for infusion. In our experience, most patients
present to the CT scanner with an intravenous line already inserted in only one arm, thus
removing the CT technologist from consideration. The arm of insertion is influenced by
patient or provider preference, as well as limitations to access such as the layout of
furniture or other obstacles at the bedside in crowded Emergency Departments. Patients
may prefer one side over the other as a result of hand dominance, previous intravenous
line insertion experiences, or other less definable reasons. In our study population
though, there was no difference between the number of left and right-sided infusions,
despite the increased population prevalence of right-handed individuals. To remove this
potential confounder we could have prospectively enrolled patients and mandated that
they have intravenous access on a specific randomly determined side before they came to
the CT scanner.
Another limitation in our data collection process is the absence of patient weight and
the apparent discrepancy between the volumes of contrast recorded versus the amount
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dictated by the protocol. We chose not to collect or include patient weight as a potential
confounding variable in our analysis. Although our hospital’s order entry system
requires clinicians to input the patient’s weight, this value is commonly not provided.
Additionally, it is our experience that patient weight, when present, is only an estimate
since most patients are not weighed on admission or initial presentation to the Emergency
Department. It is unclear why the volume of contrast recorded is sometimes different
from the protocol volume. We hypothesize that this is most likely related to an error in
recording rather than an error in following the structured protocol. However, it is safe to
assume that all cases were injected at a fixed rate of 4 cc/sec. Furthermore, the baseline
volume characteristics are equal across groups, and the multiple regression analysis
confirmed there was no statistically significant difference. Patient weight and contrast
volume are generally considered to influence vessel attenuation, but for a first pass
arterial study their influence is less important than the rate of contrast injection and blood
flow38. Since all scan times were less than 25 seconds and the bolus of contrast was
running during the entirety of the scanning, the final volume of contrast administered
should not influence the attenuation. Furthermore, the protocols on all three scanners
utilize SmartMA dose modulation which attempts to compensate for variations in body
habitus, and should thus lessen attenuation changes secondary to differences in patient
weights. As a result, we feel that the weight absence and contrast volume discrepancy
would have a minimal, if any, influence on our outcomes, and certainly not enough to
change the central conclusions reached by our analysis.
Another potential confounding variable is CHF status. As previously discussed, the
rate of blood flow has a major impact on the rate of contrast delivery, the slope of the
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attenuation curve, and thus the peak attenuation value. CHF patients have reduced
forward flow of blood which could allow for contrast pooling proximal to the site of
imaging. In our sample the prevalence of CHF was 1% versus the 2.5% estimated by the
American Heart Association39. We might have predicted a higher than normal average,
since CHF is an independent risk factor for the development of deep vein thrombosis40.
We recorded CHF status as positive if it was included in the brief clinical history inserted
by the requesting clinician or if the diagnosis of CHF was made based on the clinical
interpretation of the scan made by the radiologist. We recognize that the ordering
clinician may not have obtained a complete history or included all relevant history when
placing the order. Additionally, the scans were not re-interpreted during the image
review to ensure whether a diagnosis of CHF was appropriate. However, the low
reported prevalence of CHF was evenly distribution between the two arms. CHF
prevalence is also directly proportional to age, and there was no statistically significant
difference in age between the two infusion groups. Although our data indicate that a
number of CHF patients might not have been appropriately classified as such, there is no
reason to suspect that there is a systemic absence of classification for one particular arm
of infusion. As a result, we do not believe that this would have a major impact on our
principal outcomes.
A final identified limitation of this study is the inability to control for the location of
the intravenous access within the arm. Our records do not indicate the size of the
intravenous needle or its location on the arm of infusion. The CT pulmonary angiogram
protocol calls for an 18 gauge or larger IV to be placed in an upper extremity vein, so that
an injection rate of 4 cc/sec can be obtained. Antecubital access with a 20 gauge IV may
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provide a better bolus than hand access with an 18 gauge IV, even if both are injected at
the same rate. Given the lack of available data we are unable to control for this
possibility, although again there is no reason to suspect a systemic difference between the
arms of infusion.
In conclusion, our data and analysis indicate that the side of contrast injection did not
affect the post-contrast attenuation within the main pulmonary artery when performing
CT pulmonary angiogram examinations to evaluate for pulmonary emboli. Additionally,
the number of studies with main pulmonary artery attenuations of less than 250, 200, or
150 HU and the number of studies interpreted as indeterminate or non-diagnostic was
independent of the side of contrast injection. Finally, we were unable to identify a shelf
effect demonstrating attenuation divergence with increasing age. While in patients with
known central venous occlusions or structurally altered anatomy it may be wise to choose
the side of injection to correlate with the side of least resistance, this was not the case for
patients in the general population.
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FIGURES

Fig. 1 a-c – Attenuation over time curves for contrast infusion based on ideal conditions
(a), clinically insignificant delays (b), and clinically significant delays (c).
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Fig. 2 – Coronal reformat of a CT angiogram demonstrating series trimming to remove
evidence of arm of infusion.

Fig. 3 – Transverse slice of a CT angiogram with a region of interest (ROI) placed within
the main pulmonary artery. Attenuation values and cross-sectional area are shown.
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Fig. 4 – Flow diagram of included studies.

Fig. 5 – Left versus right arm attenuation distribution.
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Fig. 6 – Attenuation in Hounsfeld units in the right vs. left arm with 95% confidence
intervals shown.

